SCHEMBL24089990

SCHEMBL24089990

CN(C)Cc1ccc(Nc2nc3ccc(F)cc3c(=O)n2-c2cccnc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
IDO2 Q6ZQW0 1/20 0.46
PIK3CD O00329 1/20 0.46
ALOX12 P18054 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPK14 Q16539 2/20 0.39
MDM2 Q00987 1/20 0.38
ROCK2 O75116 1/20 0.37
CYP1A2 P05177 1/20 0.36
METAP2 P50579 1/20 0.36
BPTF Q12830 1/20 0.36
RAB9A P51151 1/20 0.36
PDE5A O76074 1/20 0.36
CXCR3 P49682 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24090006 0.91 TDO2 (0.51) IDO1TDO2IDO2PIK3CD
SCHEMBL24090131 0.89 MAT2A (0.44) ALOX12ALDH1A1MDM2BPTF
SCHEMBL24089988 0.88 PIK3CD (0.46) TDO2IDO2PIK3CDALOX12ALDH1A1
SCHEMBL24089947 0.88 ALOX12 (0.55) ALOX12MDM2RAB9ACXCR3
SCHEMBL24090095 0.86 PIK3CD (0.50) IDO1TDO2IDO2PIK3CDALOX12
SCHEMBL24089922 0.85 PIK3CD (0.47) TDO2IDO2PIK3CDALOX12ALDH1A1
SCHEMBL30103245 0.84 PIK3CD (0.50) IDO1TDO2IDO2PIK3CDALOX12
SCHEMBL23958245 0.84 PIK3CD (0.50) IDO1TDO2IDO2PIK3CDALOX12
SCHEMBL23065100 0.84 TDO2 (0.42) IDO1TDO2IDO2PIK3CD
SCHEMBL24090121 0.84 PIK3CD (0.43) IDO1TDO2IDO2PIK3CDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL IDO1 386/4885TDO2 2059/4885IDO2 398/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 IDO1 592/4885TDO2 1774/4885IDO2 416/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 IDO1 592/4885TDO2 1774/4885IDO2 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.